Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$53.82

-3.83 (-6.64%)

10:39
10/12/16
10/12
10:39
10/12/16
10:39

Sarepta ticks higher as Anthem review request for Exondys 51 circulated

Shares of Sarepta Therapeutics (SRPT) are moving off their lows and have turned positive as market participants circulate a review request form for Exondys 51 from Anthem (ANTM), according to trading contacts. Earlier this month, Anthem stated in a Medical Policy statement on its website that the use of eteplirsen is "considered investigational and not medically necessary for all indications, including but not limited to the treatment of Duchenne muscular dystrophy." At that time, Baird analyst Brian Skorney noted cautioned that the policy did "not mean that Anthem is not covering the drug." The analyst explained that the policy means prior authorization requirements may be stricter, but he "highly doubts" that eligible patients will be denied coverage. In morning trading, Sarepta shares are up 2% to $54.94. Reference Link

  • 06

    Nov

SRPT Sarepta
$53.82

-3.83 (-6.64%)

09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $68
PIPR
Overweight
Piper Jaffray ups Sarepta target to $68 on Summit deal
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics (SRPT) to $68 from $64 after the company licensed Summit Therapeutics' (SMMT) ezutromid to treat Duchenne Muscular Dystrophy in Europe, Turkey and the Commonwealth of Independent States. The deal is a smart way for Sarepta to capitalize on its lead in DMD with the recent FDA approval of Exondys51, Tenthoff tells investors in an intraday research note. His new price target of $68 reflects the value of ezutromid. Tenthoff reiterates an Overweight rating on Sarepta. The stock is up 1% to $61.61 in late morning trading. Summit is up 94%, or $8.17, to $16.82.
10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.
10/07/16
BARD
10/07/16
NO CHANGE
Target $102
BARD
Outperform
Anthem policy does not mean insurer not covering Sarepta drug, says Baird
Baird analyst Brian Skorney noted Anthem (ANTM) has categorized Sarepta (SRPT) Duchenne muscular dystrophy drug Exondys 51 as "not medically necessary" in a new coverage policy, but he cautions this "does not mean that Anthem is not covering the drug." The analyst explains that the policy means prior authorization requirements may be stricter, but he "highly doubts" that eligible patients will be denied coverage. Skorney, who adds that other large insurers appear to have favorable coverage for the drug, keeps an Outperform rating and $102 price target on Sarepta shares.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

11:17
01/22/18
01/22
11:17
01/22/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$91.66

0.59 (0.65%)

11:16
01/22/18
01/22
11:16
01/22/18
11:16
Technical Analysis
Technical Earnings Preview: Procter & Gamble near life highs before news »

The stock is not far from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

$NYE

NYSE Market Internals

11:16
01/22/18
01/22
11:16
01/22/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$55.80

0.63 (1.14%)

11:15
01/22/18
01/22
11:15
01/22/18
11:15
Options
Continental Resources put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
01/22/18
01/22
11:15
01/22/18
11:15
General news
Treasury announced a $35 B 4-week bill offering for Tuesday »

Treasury announced a $35…

11:15
01/22/18
01/22
11:15
01/22/18
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
01/22/18
01/22
11:15
01/22/18
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

LQ

La Quinta

$20.32

0.135 (0.67%)

, WYN

Wyndham

$126.65

-0.34 (-0.27%)

11:13
01/22/18
01/22
11:13
01/22/18
11:13
Downgrade
La Quinta, Wyndham rating change  »

La Quinta downgraded to…

LQ

La Quinta

$20.32

0.135 (0.67%)

WYN

Wyndham

$126.65

-0.34 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

11:10
01/22/18
01/22
11:10
01/22/18
11:10
Periodicals
KGI's Kuo says Apple will discontinue first-generation iPhone X, MacRumors says »

Apple will discontinue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

11:04
01/22/18
01/22
11:04
01/22/18
11:04
General news
4-Week Bill Announcement Offering Amount data reported »

4-Week Bill Announcement…

ZIOP

Ziopharm

$4.28

-0.08 (-1.83%)

11:02
01/22/18
01/22
11:02
01/22/18
11:02
Periodicals
Ziopharm rise due to 'stupid money' inflow, Feuerstein says »

Adam Feuerstein tweeted:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQ

La Quinta

$20.35

0.17 (0.84%)

11:02
01/22/18
01/22
11:02
01/22/18
11:02
Downgrade
La Quinta rating change  »

La Quinta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWBI

Northwest Bancshares

$17.09

0.24 (1.42%)

11:01
01/22/18
01/22
11:01
01/22/18
11:01
Earnings
Northwest Bancshares reports Q4 EPS 22c, consensus 22c »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$6.10

-0.34 (-5.28%)

11:01
01/22/18
01/22
11:01
01/22/18
11:01
Hot Stocks
AK Steel: Ladle at Middletown Works caster malfunctioned, no injuries reported »

AK Steel said that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

XLU

Utilities SPDR

$50.47

0.48 (0.96%)

11:00
01/22/18
01/22
11:00
01/22/18
11:00
Options
Renewed interest in SPDR Utility Fund Mar 49 puts »

Renewed interest in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWBI

Northwest Bancshares

$17.09

0.24 (1.42%)

10:59
01/22/18
01/22
10:59
01/22/18
10:59
Hot Stocks
Northwest Bancshares boosts quarterly dividend 6.25% to 17c per share »

The company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$11.61

0.4715 (4.23%)

10:56
01/22/18
01/22
10:56
01/22/18
10:56
Hot Stocks
Barclays: Nehren as head of statistical modeling & development, Equities »

Barclays announces the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALGN

Align Technology

$269.46

-1.24 (-0.46%)

10:55
01/22/18
01/22
10:55
01/22/18
10:55
Options
Align Technology put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

HPQ

HP Inc.

$23.78

0.075 (0.32%)

10:55
01/22/18
01/22
10:55
01/22/18
10:55
Conference/Events
HP Inc. to hold a webcast »

Global Head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

DXCM

Dexcom

$56.05

-0.23 (-0.41%)

, MDT

Medtronic

$85.75

-0.93 (-1.07%)

10:54
01/22/18
01/22
10:54
01/22/18
10:54
Conference/Events
Piper Jaffray medical technology analyst holds analyst/industry conference call »

Medical Technology…

DXCM

Dexcom

$56.05

-0.23 (-0.41%)

MDT

Medtronic

$85.75

-0.93 (-1.07%)

PODD

Insulet

$75.18

2.29 (3.14%)

TNDM

TNDM

ABT

Abbott

$59.07

-0.24 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

IBCP

Independent Bank

$23.85

0.25 (1.06%)

10:46
01/22/18
01/22
10:46
01/22/18
10:46
Hot Stocks
Independent Bank raises quarterly cash dividend 25% to 15c per share »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

FCAU

Fiat Chrysler

$24.07

0.14 (0.59%)

10:45
01/22/18
01/22
10:45
01/22/18
10:45
Options
Fiat Chrysler call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
01/22/18
01/22
10:45
01/22/18
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

TEVA

Teva

$20.77

0.07 (0.34%)

10:44
01/22/18
01/22
10:44
01/22/18
10:44
Recommendations
Teva analyst commentary  »

Teva failed study removes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NJR

New Jersey Resources

$39.10

0.15 (0.39%)

10:40
01/22/18
01/22
10:40
01/22/18
10:40
Hot Stocks
New Jersey Resources says FERC approves PennEast pipeline »

New Jersey Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 08

    Feb

  • 25

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.